Centessa Pharmaceuticals PLC ADR CNTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CNTA is a good fit for your portfolio.
News
-
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
-
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
-
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
-
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
-
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
-
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
Trading Information
- Previous Close Price
- $9.40
- Day Range
- $8.68–9.53
- 52-Week Range
- $3.96–12.45
- Bid/Ask
- $9.46 / $10.43
- Market Cap
- $948.89 Mil
- Volume/Avg
- 2.3 Mil / 417,269
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 132.76
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 75
- Website
- https://www.centessa.com
Valuation
|
Metric
|
CNTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.96 |
Price/Sales | 132.76 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CNTA
|
|---|---|
Quick Ratio | 7.51 |
Current Ratio | 8.00 |
Interest Coverage | −17.84 |
Quick Ratio
CNTA
Profitability
|
Metric
|
CNTA
|
|---|---|
Return on Assets (Normalized) | −30.51% |
Return on Equity (Normalized) | −43.07% |
Return on Invested Capital (Normalized) | −33.60% |
Return on Assets
CNTA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vrwymdfwp | Vrpvv | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ysrsqsyf | Bykqq | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ycpsxtvhj | Gkckrs | $99.5 Bil | |
MRNA
| Moderna Inc | Ltpkbmyyw | Cqst | $38.8 Bil | |
ARGX
| argenx SE ADR | Jlsmycjs | Bkpbg | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Pddnrkml | Fwks | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wbqlnvfc | Nqcygv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kqqyxskzc | Ykxljz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bcxtlkgdpm | Xvwxxh | $12.5 Bil | |
INCY
| Incyte Corp | Rlmlckvp | Zwsgyk | $11.6 Bil |